Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Zentek Ltd V.ZEN

Alternate Symbol(s):  ZTEK

Zentek Ltd. is a Canada-based graphene technology company. The principal business of the Company is to develop opportunities in the graphene and related nano-materials industry based on its intellectual property, patents and unique Albany graphite. The Company is focused on the research, development, and commercialization of graphene-based products. The Company's technology helps filter and deactivate pathogens to reduce the risk of transmission. The Company is focused on commercializing ZenGUARD, which is a hydrophilic, water attracting coating that adsorbs bacteria and virus-laden aerosols and deactivates them, increasing public safety, and reducing the risk of transmission of COVID and other pathogens. The Company is developing a graphene-based fuel additive that can reduce greenhouse gas (GHG) emissions from diesel and bio-diesel fuels. The Company’s developments include Aptamers & Rapid Detection and Graphene-Oxide Synthesis & Graphene Synthesis.


TSXV:ZEN - Post by User

<< Previous
Bullboard Posts
Next >>
Post by Ridgebackon Jan 07, 2022 9:54am
297 Views
Post# 34292467

Zentek call

Zentek call

Phoenix, Arizona--(Newsfile Corp. - January 6, 2022) - The Stock Day Podcast welcomed Zentek Ltd. (OTC Pink: ZENYF) ("the Company"), an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. CEO of the Company, Dr. Francis Dube, joined Stock Day host Everett Jolly.

Jolly began the interview by asking about the Company's background and current projects. "We're really a healthcare, health technology company, and we've been focused on that for the last eighteen months with the COVID pandemic," said Dr. Dube. "We're basically a research and development company," he added. "We develop and commercialize IP."

"Last year, we started working on a new technology that would help make masks better," continued Dr. Dube. "When we talked last October, we had just filed a provisional patent in the US for the new technology that enabled masks to have a 99.99% bacterial and viral filtration efficiency," he explained. "Within a year we went from filing a patent to having regulatory approvals here in Canada and we have filed a 510K pre-submission in the US, and we are now also moving into Europe with our regulatory applications."

"Could you bring us up-to-date on the status of financing?" asked Jolly. "We are actually at the tail end of a $33 million Canadian raise," shared Dr. Dube. "We now have a full treasury to be able to expedite our business plan," he added. "We're going to have the capacity to produce a lot of masks, we're talking hundreds of millions of masks per month."

"We're also working on a really novel detection technology, which could help diagnose COVID within ten minutes, but at a PCR level sensitivity," said Dr. Dube.

"Are you expecting to uplist on the Nasdaq?" asked Jolly. "We officially applied to the Nasdaq on October 13th," shared Dr. Dube. "We do expect our shares to be uplisted from the Pink Sheets to the Nasdaq hopefully later this month."

The conversation then turned to the Company's 2022 goals. "We've been focused on getting our masks to market and that is still our number one project right now," said Dr. Dube. "We want to start generating revenue as a healthcare IP development company and we expect those revenues to have significant margins," he said, noting the market cap potential of those margins.

"Secondary to that is really developing our rapid detection technology," continued Dr. Dube. "We have a global exclusive license to use this technology from McMaster University," he said. "We're going to be pushing really hard to bring that to market as soon as possible."

To close the interview, Dr. Dube elaborated on the Company's significant 2021 achievements, as well as their 2022 goals, and encouraged listeners to stay up-to-date on the Company's current and upcoming projects.

To hear Francis Dube's entire interview, follow the link to the podcast here: https://audioboom.com/posts/8008341-zentek-ltd-discusses-c-33-million-financing-and-2022-goals-with-the-stock-day-podcast.

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/.

<< Previous
Bullboard Posts
Next >>